COX2 Antibody (YA791)

(Synonyms: COX2, PTGS2, Prostaglandin G/H synthase 2, Cyclooxygenase-2, PHS II, Prostaglandin H2 synthase 2, Prostaglandin-endoperoxide synthase 2, COX-2, PGH synthase 2, PGHS-2)
3 Cited Publications
Avis client

Based on 3 publication(s) in Google Scholar

COX2 Antibody (YA791) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to COX2.

For research use only. We do not sell to patients.
  • Host:

    Mouse

  • Isotype:

    IgG

  • Application:

    WB, IHC-P, FC

  • Reactivity :

    Human, Mouse, Rat

  • Formulation:

    Supplied in 1*PBS (pH7.4), 0.2% BSA and 50% Glycerol. Preservative: 0.05% Sodium Azide.

  • Conjugation:
    Non-conjugated

Applications

Application
WB Info
WB: Western Blot
IHC-P Info
IHC-P: Immunohistochemistry-Paraffin
FC Info
FC: Flow Cytometry
Dilution Ratio 1:500-1:1000 1:50-1:200 1:50-1:100

Product Details

Description

COX2 Antibody (YA791) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to COX2.

  • Host Mouse
  • Clonality Monoclonal
  • Species Reactivity
    Human, Mouse, Rat
  • Observed Molecular Weight
    Observed band size: 60 kDa Info
    Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
  • Calculated Molecular Weight Predicted band size: 69 kDa
Species Reactivity Database
Immunogen

Synthetic peptide within C-terminal human COX2.

Sensitivity

Endogenous

Purification

Protein G affinity purified.

Conjugation

Non-conjugated

Modification

Unmodified

Isotype

IgG

RRID

AB_3102074

Product Properties

  • Appearance

    Solution

  • Formulation

    Supplied in 1*PBS (pH7.4), 0.2% BSA and 50% Glycerol. Preservative: 0.05% Sodium Azide.

  • Concentration

    Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration

  • Storage & Stability

    Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

  • Livraison

    Shipping with blue ice.

Verification Images

  • Experimental Validation Results for COX2 Antibody (YA791)
    Western blot analysis of extracts from A549 (lane 2(20μg), A549 (lane 3(40μg), using COX2 Antibody. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in TBST for 2 hour at room temperature. The primary antibody and Loading control antibody (Beta Actin, HY-P80438, 1/3000) was used in 5% BSA in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (HY-P8004/HY-P8001, 1/10,000) was used for 1 hour at room temperature.
  • Experimental Validation Results for COX2 Antibody (YA791)
    Immunohistochemical analysis of paraffin-embedded rat colon using COX2 antibody. The section was pre-treated using heat mediated antigen retrieval with EDTA (pH 9.0) for 14 minutes. The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with TBST, and then probed with the primary antibody (HY-P80090, 1/100) for 30 minutes at room temperature. The detection was performed using Polymer HRP-conjugated Goat Anti-Mouse/Rabbit lgG(H&L) secondary antibody (HY-P83652). DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
  • Experimental Validation Results for COX2 Antibody (YA791)
    Immunohistochemical analysis of paraffin-embedded human colon cancer using COX2 antibody. The section was pre-treated using heat mediated antigen retrieval with EDTA (pH 9.0) for 14 minutes. The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with TBST, and then probed with the primary antibody (HY-P80090, 1/100) for 30 minutes at room temperature. The detection was performed using Polymer HRP-conjugated Goat Anti-Mouse/Rabbit lgG(H&L) secondary antibody (HY-P83652). DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
  • Experimental Validation Results for COX2 Antibody (YA791)
    Immunohistochemical analysis of paraffin-embedded human kidney using COX2 antibody. The section was pre-treated using heat mediated antigen retrieval with EDTA (pH 9.0) for 14 minutes. The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with TBST, and then probed with the primary antibody (HY-P80090, 1/100) for 30 minutes at room temperature. The detection was performed using Polymer HRP-conjugated Goat Anti-Mouse/Rabbit lgG(H&L) secondary antibody (HY-P83652). DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
  • Experimental Validation Results for COX2 Antibody (YA791)
    Immunohistochemical analysis of paraffin-embedded mouce small intestine using COX2 antibody. The section was pre-treated using heat mediated antigen retrieval with EDTA (pH 9.0) for 14 minutes. The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with TBST, and then probed with the primary antibody (HY-P80090, 1/100) for 30 minutes at room temperature. The detection was performed using Polymer HRP-conjugated Goat Anti-Mouse/Rabbit lgG(H&L) secondary antibody (HY-P83652). DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
  • Experimental Validation Results for COX2 Antibody (YA791)
    Immunohistochemical analysis of paraffin-embedded mouce lung using COX2 antibody. The section was pre-treated using heat mediated antigen retrieval with EDTA (pH 9.0) for 14 minutes. The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with TBST, and then probed with the primary antibody (HY-P80090, 1/100) for 30 minutes at room temperature. The detection was performed using Polymer HRP-conjugated Goat Anti-Mouse/Rabbit lgG(H&L) secondary antibody (HY-P83652). DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
  • Experimental Validation Results for COX2 Antibody (YA791)
    Immunohistochemical analysis of paraffin-embedded mouce prostate using COX2 antibody. The section was pre-treated using heat mediated antigen retrieval with EDTA (pH 9.0) for 14 minutes. The tissues were blocked in 5% BSA for 30 minutes at room temperature, washed with TBST, and then probed with the primary antibody (HY-P80090, 1/100) for 30 minutes at room temperature. The detection was performed using Polymer HRP-conjugated Goat Anti-Mouse/Rabbit lgG(H&L) secondary antibody (HY-P83652). DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.

Background

  • Function

    Cyclooxygenase-2 (COX-2) is an inducible enzyme catalyzing the conversion of arachidonic acid to prostaglandin endoperoxides, central to prostanoid biosynthesis and inflammatory signaling[1][2]. Mechanistically, COX-2 activity is regulated by both its catalytic and allosteric subunits, allowing modulation by fatty acids and selective inhibitors, distinguishing it from constitutive COX-1[2]. COX-2 is strongly upregulated in response to pro-inflammatory cytokines, hypoxia, and tumor microenvironment signals, orchestrating prostaglandin E2 (PGE2) production and downstream activation of NF-κB and PI3K-Akt pathways[3][4][5]. In disease models, COX-2 contributes to cancer progression, atherosclerosis, and migraine through modulation of immune responses, vascular smooth muscle activity, and neuronal-glial interactions[6][7][5]. Compared with COX-1, COX-2 expression is more context-dependent and spatially regulated, being highly inducible in endothelial cells, arterial versus venous smooth muscle, and neuronal populations under stress or inflammatory stimuli[8][9][10]. Experimental studies demonstrate COX-2 as a critical mediator of ischemic preconditioning in the heart, providing cardioprotection via PGE2 and PGI2 signaling[11]. Selective COX-2 inhibitors, including synthetic NSAIDs and dual COX/LOX modulators, are utilized to interrogate COX-2 function and develop anti-inflammatory therapies with reduced gastrointestinal and cardiovascular side effects[3][12]. Agonist studies further highlight receptor-mediated induction of COX-2, exemplifying its role in colon carcinoma and trigeminal ganglia models[13][7].

  • Subcellular Localization

    Microsome membrane; Peripheral membrane protein; Endoplasmic reticulum membrane; Peripheral membrane protein; Nucleus inner membrane; Peripheral membrane protein; Nucleus outer membrane; Peripheral membrane protein

  • Expression


    Induction:By cytokines and mitogens. Up-regulated by IL1B (PubMed:26282205, PubMed:9545330) . Up-regulated by lipopolysaccharide (LPS) (PubMed:9545330)

  • Subunit

    Homodimer

  • SwissProt ID

    P35354

  • Gene ID
  • Synonyms

    COX2, PTGS2, Prostaglandin G/H synthase 2, Cyclooxygenase-2, PHS II, Prostaglandin H2 synthase 2, Prostaglandin-endoperoxide synthase 2, COX-2, PGH synthase 2, PGHS-2

  • Research Field

    Immunology

[1]. Smith FG, et al. Cyclooxygenase (COX) Inhibitors and the Newborn Kidney. Pharmaceuticals (Basel). 2012 Oct 25;5(11):1160-76. [Content Brief]

[2]. Ahmadi M, et al. Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors. RSC Med Chem. 2022 Feb 14;13(5):471-496. [Content Brief]

[3]. Bolli R, et al. Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res. 2002 Aug 15;55(3):506-19. [Content Brief]

[4]. Kirkby NS, et al. COX-2 protects against atherosclerosis independently of local vascular prostacyclin: identification of COX-2 associated pathways implicate Rgl1 and lymphocyte networks. PLoS One. 2014 Jun 2;9(6):e98165. [Content Brief]

[5]. Segelcke D, et al. The role of the spinal cyclooxygenase (COX) for incisional pain in rats at different developmental stages. Eur J Pain. 2020 Feb;24(2):312-324. [Content Brief]

[6]. Chatzipieris FP, et al. Recent advances in dual COX/LOX inhibitor design (2020-2024). Life. 2026;16(1):163. [Content Brief]

[7]. Yang WL, et al. Cholinergic receptor up-regulates COX-2 expression and prostaglandin E(2) production in colon cancer cells. Carcinogenesis. 2000 Oct;21(10):1789-93. [Content Brief]

[8]. Hsieh HL, et al. c-Src-dependent EGF receptor transactivation contributes to ET-1-induced COX-2 expression in brain microvascular endothelial cells. J Neuroinflammation. 2012 Jul 2;9:152. [Content Brief]

[9]. Neeb L, et al. IL-1β stimulates COX-2 dependent PGE₂ synthesis and CGRP release in rat trigeminal ganglia cells. PLoS One. 2011 Mar 4;6(3):e17360. [Content Brief]

[10]. Chen S, et al. 288 The COX-2 pathway as a mediator of resistance to anti-PD-1 therapy. J Immunother Cancer. 2021;9(Suppl 2):A312.

[11]. Bishop-Bailey D, et al. Differential induction of cyclooxygenase-2 in human arterial and venous smooth muscle: role of endogenous prostanoids. Arterioscler Thromb Vasc Biol. 1998 Oct;18(10):1655-61. [Content Brief]

[12]. Majumder M, et al. COX-2 Elevates Oncogenic miR-526b in Breast Cancer by EP4 Activation. Mol Cancer Res. 2015 Jun;13(6):1022-33. [Content Brief]

[13]. Scott KF, et al. Functional coupling and differential regulation of the phospholipase A2-cyclooxygenase pathways in inflammation. J Leukoc Biol. 1999 Oct;66(4):535-41. [Content Brief]

[14]. Smith WL, et al. Interactions of fatty acids, nonsteroidal anti-inflammatory drugs, and coxibs with the catalytic and allosteric subunits of cyclooxygenases-1 and -2. J Biol Chem. 2019 Feb 1;294(5):1697-1705. [Content Brief]

View More

COX2 Antibody (YA791) Related Classifications

MOQ
Minimum order quantity
100 mg

Obtenir un devis En stock

Other size
Obtenir un devis
Please select quantity
Amount: USD 0.00